Major depressive disorder medications

Access the latest research on major depressive disorder medications

When you’re seeking access to the most recent research on major depressive disorder medications, you’ll find evidence-based, peer-reviewed articles on that explore the latest pharmacological advances. offers a wide range of original research, reports, and analysis that provide scientifically rigorous information about all aspects of major depression or major depressive disorder (MDD), including moderate major depressive disorderrecurrent major depressive disorder, and MDD diagnosis based on DSM 5 major depressive disorder criteria.

In coordination with the CME Institute (CME of Physicians Postgraduate Press, Inc., also offers opportunities to earn CME credits related to major depressive disorder medications and many other topics. With CME credits on, you can more easily satisfy your CME requirements despite a busy schedule.

Register today as a user on to explore all the benefits of this leading website. Or subscribe to The Journal of Clinical Psychiatry to enjoy full access to two decades of authoritative research on MDD, recurrent major depression, and major depressive disorder medications, along with many other areas of psychiatry and mental health.

The most up-to-date information on MDD medications and treatment publishes the latest information on mental health topics from two separate sources of psychiatric research.

The Journal of Clinical Psychiatry (JCP) is among the leading sources in the field for peer-reviewed, evidence-based articles on many areas of psychiatry and psychopharmacology. JCP has been a leading psychiatric resource for more than 75 years and is among with top 10 most-cited journals in the field of psychiatry. Content in JCP is geared toward psychiatrists and other mental health professionals.

The Primary Care Companion for CNS Disorders (PCC) is a peer-reviewed publication that is dedicated to advancing the clinical expertise of primary care physicians and other healthcare professionals who treat patients with mental and neurologic illnesses. This online-only journal aims to provide research of direct clinical utility and to give a voice to clinician researchers.

Research related to major depressive disorder medications on includes titles such as:

Depression (MDD)

Explore Topic

Earn CME credits with activities on major depressive disorder medications

As a registered user on, you can earn AMA PRA Category 1 CreditsTM for activities related to major depressive disorder medications and other subjects. CME activities are provided by the CME Institute, which is accredited by the Accreditation Counsel for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The CME Institute also provides an easy way to track your activity and print certificates and transcripts once you have earned CME credit.

CME activities related to major depressive disorder medications include titles such as:

FAQs on research into major depressive disorder medications

You can view all articles from The Primary Care Companion and certain supplements and articles from The Journal of Clinical Psychiatry by simply registering for free on For unrestricted access to all current and archived material on the website, you’ll need a subscription to JCP.

Yes. JCP offers online-only as well as print/online subscriptions. View the JCP subscription page on the website for more information and pricing.

Yes. CME activities are accredited by the Accreditation Council for Continuing Medical Education (ACCME). AMA PRA Category 1 CreditsTM are awarded for CME activities completed through and

Most CME activities available on are free of charge, though occasionally a $10 processing fee will apply.

Register or subscribe for research on major depressive disorder medications

To access resources related to major depressive disorder medications on, you may register for free or choose a paid subscription to JCP.

As a registered user, you can view the full text of all articles from The Primary Care Companion as well as supplements and some free articles from The Journal of Clinical Psychiatry. You’ll also have access to podcasts, blogs, and CME offerings, along with a free MyCME account. Your MyCME account automatically keeps track of your activity on the website and the CME credits you have earned.

When you subscribe to JCP, you’ll enjoy unrestricted access to all resources on major depressive disorder medications and many other subjects. You can search for and view articles from issues of JCP from 1997 to the present and view new issues the day they are released. You can also access online-only and online-first articles that are published weekly.

Get updates on MDD medications delivered daily to your inbox

When you register for free on, you can sign up to receive daily email alerts, or Elerts, that bring notification of new articles directly into your inbox. Elerts provide updates on new research, blogs, CME offerings, and other postings, as well as the table of contents for upcoming issues of JCP and PCC. With Elerts from, you’ll always have the latest information about major depressive disorder medications and many other subjects covered by


Published by Physicians Postgraduate Press, Inc., is a leading source of evidence-based, peer-reviewed research and CME activities from three sources: The Journal of Clinical Psychiatry, The Primary Care Companion for CNS Disorders, and the CME Institute at

Clinicians who work with patients with mental health disorders and CNS disorders will find a large assortment of information and CME activities on Topics covered by material on include diagnosis of manic depressioncriteria for major depressive disorder according to the definition of major depressive disorder in DSM-5signs of ADHD in adults and treatment for ADHD in children and adults; research on disorganized schizophrenia symptoms; and the latest psychiatry research and articles on family, geriatric, interventional, integrated, functional, and general psychiatry.

Sign-up to stay
up-to-date today!


Already registered? Sign In

Original Research

Generalizability of the Results of Efficacy Trials in First-Episode Schizophrenia: Comparing Outcome and Study Discontinuation of Groups of Participants in the Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial

First-episode schizophrenia patients with suicidal ideation and substance use disorder are often excluded from clinical trials. Omitting...